Evotec's Research Chief Exits as the Market Waits for the Turnaround to Prove Itself

Evotec CSO Cord Dohrmann leaves the executive board on September 30, mid-restructuring, as the drug developer hunts a successor and defends cut 2026 guidance.

Evotec's leadership shake-up has now reached the laboratory. Chief Scientific Officer Cord Dohrmann will leave the Hamburg-based drug developer on September 30, departing the executive board by mutual agreement after more than a decade in the role. The company has begun the hunt for a successor, but no replacement has been named.

Dohrmann, a board member since 2010, was the architect of much of Evotec's scientific identity — notably the iPSC cell therapy and Omics technology platforms that underpin its drug discovery offering. His exit lands in the middle of a broader management reshuffle. Claire Hinshelwood only took over as Chief Financial Officer on May 1, stepping in after Paul Hitchin vacated the CFO seat at the end of April for personal reasons. Hinshelwood brought more than 30 years of financial leadership experience, most recently as Group CFO at BMI Group.

Equity markets took the news in stride. The stock added 4.2% on the day to close at EUR 2.97, though it has still shed 45% since the start of the year — a reminder of how far sentiment has fallen.

A Restructuring That Leaves Little Room for Error

The personnel changes coincide with "Horizon," the cost-cutting and restructuring program management is running to resize the business for tougher market conditions. Whether the board can hold the line on its sharply downgraded full-year targets is now the central question for investors.

The summer dealt a heavy blow to credibility. In July, Evotec slashed its 2026 guidance: group revenue is now expected between EUR 570 million and EUR 610 million, down from an earlier target of EUR 700 million to EUR 780 million. Profitability took an even harder hit. Adjusted EBITDA is projected to come in negative for the year, at minus EUR 70 million to minus EUR 105 million, a stark reversal from the previously flagged positive operating result of up to EUR 40 million. First-half revenue totaled EUR 300.1 million, with adjusted EBITDA at minus EUR 42.7 million.

Shifts in strategic partnership revenue weighed on the forecast, the company said, while insisting that Horizon's cost reductions remain on schedule. CFO Hinshelwood reinforced that message roughly two weeks ago at a Morgan Stanley investor conference, telling attendees that business indicators were moving in the right direction and that the pipeline of potential deals remained robust. Investors, however, want hard evidence rather than signals.

Pipeline Progress Offers a Counterweight

The scientific base, at least, is still producing. About two weeks ago, Just – Evotec Biologics moved an antibody program against orthopoxviruses into Phase I for the U.S. Department of Defense. Roughly a month earlier, Evotec struck a research collaboration with Plectonic Biotech to develop new immuno-oncology approaches for solid tumors, targeting T-cell-activating mechanisms.

Berenberg remains cautious. After a conversation with CEO Christian Wojczewski, the private bank reiterated its "Hold" rating on Friday with a price target of EUR 3.60. Reaching that level would give shareholders a meaningful rebound — provided institutional confidence returns.

Two Paths From Here

In the bull case, Horizon delivers faster than expected. If operating costs fall sustainably and core-business efficiency improves, Evotec could return to profitability ahead of schedule. A swift appointment of an internationally respected scientific leader would add momentum to that story.

The bear case leans on what Dohrmann's departure costs. Losing his networks and research ties could slow ongoing partnership talks with pharma groups. Without stable leadership in discovery, the pursuit of lucrative milestone projects could stall, further clouding revenue visibility. Add the risk of a missed restructuring target — revenue stuck at the low end of the range, or adjusted EBITDA sinking deeper into the red — and the SDAX-listed group faces a prolonged dry spell. Demand for contract research remains difficult, with large pharma companies still managing external development budgets tightly. If the hoped-for pickup in demand fails to materialize, new lows are possible.

The Chart and the Calendar

Technically, the near-term question is whether the stock can defend its recent floor. The shares touched a low of EUR 2.71 on September 25. Holding that level keeps a stabilization phase alive; a decisive break below it would leave little chart support in the way of further declines.

The next real catalyst is already circled: on November 5, Evotec publishes final figures for the third quarter of 2026. That report will show whether cost savings are already supporting profitability and whether the company can credibly stand behind its reduced guidance. Until then, the market has little choice but to wait — and to weigh whether Dohrmann's exit clears the path for a faster reset or makes the operational heavy lifting that much harder.